Anthracycline and anthraquinone anticancer agents: current status and recent developments.
The clinical treatment of neoplastic diseases relies on the complementary procedures of surgery, radiation treatment, immunotherapy and chemotherapy. The latter technique has matured from its earliest applications of mustard alkylating agents in the 1940s to an increasingly rationally based discipline, which is contributing significantly to the management of human malignancies. As the field of chemotherapy matured, several promising natural anticancer agents were identified. However, a more urgent need soon arose from the common experience of clinically limiting toxicities of most anticancer drugs, i.e. the necessity to develop less toxic clinical drug candidates. Thus, the medicinal chemist turned towards analog development involving certain anthraquinones. Hand-in-hand with this considerable synthetic effort, which uncovered several promising clinical leads, biochemical pharmacology, or study of the mechanisms of action of clinical anticancer agents, afforded deeper insight into drug metabolism and mode of action. More recently, therefore, the field of synthetic organic chemistry, which has been complemented by the methods of microbial chemistry, has been faced with new synthetic challenges, occasioned by the identification of hitherto unrecognized cellular targets for anticancer drugs, such as topoisomerases and helicases. The armementarium of the oncologist currently includes about 40-50 clinically useful chemical agents. The paradigm of cytotoxic anticancer agents is doxorubicin, an anthracycline, which is still amongst the most widely prescribed and effective of anticancer agents. The review attempts to summarize the discovery of anthracyclines and the elucidation of their several mechanisms of action and efforts towards improvement of their therapeutic efficacy.
Department of Chemistry, University of Alberta, Edmonton, Canada.
J W
JW
Lown
D000606:Amino Sugars / Q000737:chemistry; D000818:Animals; D000880:Anthraquinones / Q000737:chemistry*; D000903:Antibiotics, Antineoplastic / Q000096:biosynthesis / Q000737:chemistry* / Q000145:classification*; D000970:Antineoplastic Agents / Q000737:chemistry* / Q000494:pharmacology*; D002625:Chemistry, Organic / Q000639:trends; D004265:DNA Helicases / Q000187:drug effects; D004264:DNA Topoisomerases, Type I / Q000187:drug effects; D004347:Drug Interactions; D006801:Humans; D013237:Stereoisomerism; D013329:Structure-Activity Relationship
D000606:Amino Sugars; D000880:Anthraquinones; D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D004265:DNA Helicases; D004264:DNA Topoisomerases, Type I